Results 31 to 40 of about 9,412 (255)
Inflammatory Bowel Diseases, 2021 IntroductionCoronavirus Disease 2019 (COVID-19) is an ongoing public health crisis that has sickened or precipitated death in millions. The etiologic agent of COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), infects the intestinal ...
David M. Alvarado +9 more
semanticscholar +2 more sources
Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α [PDF]
The Korean Journal of Internal Medicine, 2022 The incidence and prevalence of inflammatory bowel diseases (IBDs) are rapidly increasing worldwide. IBDs are considered an emerging problem not only in Western countries but also in developing counties.
Jihye Park, Jae Hee Cheon
doaj +1 more source
The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. [PDF]
PLoS ONE, 2014 The anti-inflammatory agent, mesalamine (5-aminosalicylic acid) has been shown to decrease mucosal inflammation in ulcerative colitis. The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial ...
Ma Somsouk +15 more
doaj +1 more source
Journal of Clinical Medicine, 2021 Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease. Fecal microbial transplantation (FMT) is a promising alternative treatment.
J. Březina +14 more
semanticscholar +1 more source
Canadian Journal of Gastroenterology and Hepatology, 2016 Background. Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate (“5-ASA”), mesalamine suppository, or mesalamine enema (“UP Rx”). Little is known about their effectiveness in practice. Methods. Using a US health insurance
James M. Richter +2 more
doaj +1 more source
Design and Characterization of Mesalamine Loaded Nanoparticles for Controlled Delivery System [PDF]
Nanomedicine Research Journal, 2016 Objective(s): Nanoparticles (NPs) are known for their specific accumulation in the inflamed tissues of the colon and thus allow a selective delivery to the site of inflammation with minimum adverse effects.
Simin Seifirad +4 more
doaj +1 more source
Toxins, 2021 Colibactin is a genotoxin produced primarily by Escherichia coli harboring the genomic pks island (pks+ E. coli). Pks+ E. coli cause host cell DNA damage, leading to chromosomal instability and gene mutations.
Min Tang-Fichaux +3 more
semanticscholar +1 more source
Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis
Case Reports in Medicine, 2018 Development of cardiac manifestations in patients diagnosed with inflammatory bowel disease undergoing treatment with mesalamine is a rare. When this occurs, it can be difficult to tease out the primary etiology, as both IBD and mesalamine can cause ...
Kelechukwu U. Okoro +2 more
doaj +1 more source
Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease [PDF]
Intestinal Research, 2020 Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis.
Ajit Sood +23 more
doaj +1 more source
Journal of Pharmaceutical and Biological Sciences, 2021 The aim of the present study was to formulate solid dispersion (SD) of Mesalamine to enrich the aqueous solubility and dissolution rate. Mesalamine is used in the management of acute ulcerative colitis and for the prevention of relapse of active ...
A. Pawar +4 more
semanticscholar +1 more source